Avrobio Unveils Launch Plans

A clinical stage company focused on developing gene therapies targeting cancer and rare diseases — Avrobio — has announced its launch plans.

The company’s main focus will be accelerating the development of two new cell and gene therapies pioneered under Christopher Paige and Jeffrey Medin at the University Health Network in Toronto.

Phase 1 is scheduled to begin toward the middle of the year for acute myeloid leukemia and Fabry disease. The company plans to broaden its proprietary cell and gene therapy platform to treat additional indications. — Anisa Jibrell